1. Home
  2. MOB vs OKYO Comparison

MOB vs OKYO Comparison

Compare MOB & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobilicom Limited

MOB

Mobilicom Limited

HOLD

Current Price

$4.80

Market Cap

73.7M

Sector

Real Estate

ML Signal

HOLD

Logo OKYO Pharma Limited

OKYO

OKYO Pharma Limited

HOLD

Current Price

$1.40

Market Cap

87.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOB
OKYO
Founded
2008
2007
Country
Israel
United Kingdom
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
87.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MOB
OKYO
Price
$4.80
$1.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$6.33
AVG Volume (30 Days)
134.4K
63.6K
Earning Date
03-23-2026
07-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$150.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.33
$1.34
52 Week High
$11.01
$3.20

Technical Indicators

Market Signals
Indicator
MOB
OKYO
Relative Strength Index (RSI) 37.88 41.41
Support Level $4.66 N/A
Resistance Level $5.67 $1.72
Average True Range (ATR) 0.36 0.10
MACD -0.11 -0.01
Stochastic Oscillator 5.98 19.21

Price Performance

Historical Comparison
MOB
OKYO

About MOB Mobilicom Limited

Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.

About OKYO OKYO Pharma Limited

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Share on Social Networks: